We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Spencer Pharmaceutical Partners with National Pharmaceutical in the Development of Central Nervous System Disease Treatments
News

Spencer Pharmaceutical Partners with National Pharmaceutical in the Development of Central Nervous System Disease Treatments

Spencer Pharmaceutical Partners with National Pharmaceutical in the Development of Central Nervous System Disease Treatments
News

Spencer Pharmaceutical Partners with National Pharmaceutical in the Development of Central Nervous System Disease Treatments

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Spencer Pharmaceutical Partners with National Pharmaceutical in the Development of Central Nervous System Disease Treatments"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Spencer Pharmaceutical Inc. announced that it has signed a preliminary cooperative development agreement with National Pharmaceutical Corp.

According to the agreement, Spencer and National will develop central nervous disease treatments in the areas of Alzheimer and Parkinson using Spencer's drug delivery as the primary platform. The preliminary agreement calls for a share swap of 20 million restricted shares.

The final terms and conditions of the transaction will be determined in a definitive agreement. No assurances can be provided that a definitive agreement will be executed. Execution of a definitive agreement is subject to, among other things, confirming due diligence by Spencer, and other conditions and approvals by both companies' management, board of directors and shareholders, as appropriate.

"We are pleased to be working with another group in the development of treatments for CNS related diseases. As many current patented drugs are becoming free of royalties, our technology would extend the patent of treatments in Alzeimers and Parkinsons," said Dr. Arella, President of Spencer Pharmaceutical Inc.

"CNS disease treatments are one of the areas where our technology can be of use in extending the life of the patents, but we are also investigating many other areas such as anti-psychotic and anti-depressor drugs," further added Dr. Arella.
Advertisement